Aliases & Classifications for Spinocerebellar Degeneration

MalaCards integrated aliases for Spinocerebellar Degeneration:

Name: Spinocerebellar Degeneration 50 36 69
Spinocerebellar Tract Degeneration 69 28
Spinocerebellar Degenerations 51
Ataxia, Spinocerebellar 69

External Ids:

KEGG 36 H01616

Summaries for Spinocerebellar Degeneration

NINDS : 50 Ataxia often occurs when parts of the nervous system that control movement are damaged. People with ataxia experience a failure of muscle control in their arms and legs, resulting in a lack of balance and coordination or a disturbance of gait. While the term ataxia is primarily used to describe this set of symptoms, it is sometimes also used to refer to a family of disorders. It is not, however, a specific diagnosis. Most disorders that result in ataxia cause cells in the part of the brain called the cerebellum to degenerate, or atrophy. Sometimes the spine is also affected. The phrases cerebellar degeneration and spinocerebellar degeneration are used to describe changes that have taken place in a person’s nervous system; neither term constitutes a specific diagnosis. Cerebellar and spinocerebellar degeneration have many different causes. The age of onset of the resulting ataxia varies depending on the underlying cause of the degeneration. Many ataxias are hereditary and are classified by chromosomal location and pattern of inheritance: autosomal dominant,in which the affected person inherits a normal gene from one parent and a faulty gene from the other parent; andautosomal recessive, in which both parents pass on a copy of the faulty gene. Among the more common inherited ataxias are Friedreich’s ataxia and Machado-Joseph disease. Sporadic ataxias can also occur in families with no prior history. Ataxia can also be acquired. Conditions that can cause acquired ataxia include stroke, multiple sclerosis, tumors, alcoholism, peripheral neuropathy, metabolic disorders, and vitamin deficiencies.

MalaCards based summary : Spinocerebellar Degeneration, also known as spinocerebellar tract degeneration, is related to spinocerebellar ataxia 2 and dentatorubral-pallidoluysian atrophy, and has symptoms including cerebellar ataxia, ataxia and myoclonus. An important gene associated with Spinocerebellar Degeneration is ATXN1 (Ataxin 1), and among its related pathways/superpathways is Chks in Checkpoint Regulation. The drugs Clonidine and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Spinocerebellar Degeneration

Diseases related to Spinocerebellar Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Related Disease Score Top Affiliating Genes
1 spinocerebellar ataxia 2 31.7 ATXN2 ATXN3
2 dentatorubral-pallidoluysian atrophy 30.7 ATXN1 ATXN2 ATXN3
3 multiple system atrophy 1 29.6 ATXN1 GLUD1
4 spinocerebellar ataxia 1 29.4 ATXN1 ATXN3
5 aceruloplasminemia 29.1 ATXN2 ATXN3
6 friedreich ataxia 1 28.9 ATXN1 ATXN2 ATXN3
7 hereditary ataxia 28.1 ATXN1 ATXN2 ATXN3 TDP1
8 autosomal dominant cerebellar ataxia 28.1 ATXN1 ATXN2 ATXN3 TDP1
9 spinocerebellar degeneration and corneal dystrophy 12.3
10 ataxias and cerebellar or spinocerebellar degeneration 12.2
11 spinocerebellar degeneration with macular corneal dystrophy, congenital cataracts, and myopia 11.9
12 primary cerebellar degeneration 11.1
13 spinocerebellar atrophy 11.0
14 mousa al din al nassar syndrome 10.9
15 spinocerebellar ataxia, x-linked 3 10.9
16 sensory ataxic neuropathy, dysarthria, and ophthalmoparesis 10.9
17 behr syndrome 10.9
18 gamma-glutamylcysteine synthetase deficiency, hemolytic anemia due to 10.9
19 laurence-moon syndrome 10.9
20 vitamin e, familial isolated deficiency of 10.9
21 ataxia and polyneuropathy, adult-onset 10.3
22 neuronitis 10.2
23 adrenoleukodystrophy 10.1
24 neuropathy 10.0
25 motor neuron disease 10.0
26 cerebritis 10.0
27 neuronal intranuclear inclusion disease 9.9 ATXN1 ATXN3
28 langerhans cell histiocytosis 9.9
29 histiocytosis 9.9
30 spinal and bulbar muscular atrophy, x-linked 1 9.9 ATXN1 ATXN3
31 hereditary spastic paraplegia 9.7
32 hypoglycemia 9.7
33 asthma 9.7
34 hereditary sensory neuropathy 9.7
35 brainstem auditory evoked responses 9.7
36 blind loop syndrome 9.7
37 roussy-levy hereditary areflexic dystasia 9.7
38 tooth disease 9.7
39 amenorrhea 9.7
40 encephalopathy 9.7
41 fatty liver disease, nonalcoholic 1 9.7
42 myoclonus 9.7
43 celiac disease 1 9.7
44 pyruvate dehydrogenase e1-beta deficiency 9.7
45 facial hemiatrophy 9.7
46 paraneoplastic syndromes 9.7
47 ataxia-oculomotor apraxia 3 9.7
48 corneal dystrophy 9.7
49 spasticity 9.7
50 hypobetalipoproteinemia, familial, 1 9.7

Comorbidity relations with Spinocerebellar Degeneration via Phenotypic Disease Network (PDN):


Acute Cystitis Cerebral Degeneration

Graphical network of the top 20 diseases related to Spinocerebellar Degeneration:



Diseases related to Spinocerebellar Degeneration

Symptoms & Phenotypes for Spinocerebellar Degeneration

UMLS symptoms related to Spinocerebellar Degeneration:


cerebellar ataxia, ataxia, myoclonus

GenomeRNAi Phenotypes related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

25 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.5 ATXN3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.5 ATXN3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.5 ATXN3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.5 ATXN3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.5 GLUD1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.5 ATXN3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.5 ATXN3 GLUD1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.5 ATXN3 GLUD1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.5 GLUD1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.5 ATXN3 GLUD1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.5 GLUD1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.5 ATXN3

MGI Mouse Phenotypes related to Spinocerebellar Degeneration:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.02 ATXN1 ATXN2 ATXN3 GLUD1 TDP1

Drugs & Therapeutics for Spinocerebellar Degeneration

Drugs for Spinocerebellar Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
5
Metformin Approved Phase 4 657-24-9 4091 14219
6
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
7
Citalopram Approved Phase 4 59729-33-8 2771
8
Amantadine Approved Phase 4 768-94-5 2130
9 insulin Phase 4
10 Estradiol valerate Phase 4 979-32-8
11 Analgesics Phase 4,Phase 1,Phase 2
12 Adrenergic Agents Phase 4
13 Mitogens Phase 4
14 Adrenergic Agonists Phase 4
15 Adrenergic alpha-2 Receptor Agonists Phase 4
16 Adrenergic alpha-Agonists Phase 4
17 Sympatholytics Phase 4
18 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
19 Contraceptive Agents Phase 4
20 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
21 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
24 Estradiol 17 beta-cypionate Phase 4
25 Estradiol 3-benzoate Phase 4
26 Estrogens Phase 4
27 Antihypertensive Agents Phase 4,Phase 2
28 Polyestradiol phosphate Phase 4
29 Insulin, Globin Zinc Phase 4
30 Autonomic Agents Phase 4,Phase 3,Early Phase 1
31
Serotonin Phase 4 50-67-9 5202
32 Serotonin Agents Phase 4
33 Serotonin Uptake Inhibitors Phase 4
34 Muscarinic Antagonists Phase 4
35 Cholinergic Agents Phase 4,Phase 2,Phase 3
36 Cholinergic Antagonists Phase 4
37 Neurotransmitter Uptake Inhibitors Phase 4
38 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
39 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
40 Cytochrome P-450 Enzyme Inhibitors Phase 4
41 Parasympatholytics Phase 4
42 Dopamine Agents Phase 4
43 Dopamine Uptake Inhibitors Phase 4
44 Hypoglycemic Agents Phase 4,Phase 3
45 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1
46 Antidepressive Agents, Second-Generation Phase 4
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2
48 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1
49 Antiparkinson Agents Phase 4
50 Antiviral Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 120)

# Name Status NCT ID Phase Drugs
1 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
2 An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia Completed NCT01716221 Phase 4 bupropion & Citalopram;Bupropion & Placebo;Placebo & Citalopram;Placebo & Placebo
3 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
4 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
5 A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970124 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
6 A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970137 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
7 An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970111 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
8 A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970098 Phase 3 KPS-0373, High dose;KPS-0373, Low dose;Placebo
9 Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 Completed NCT01096082 Phase 2, Phase 3 Lithium Carbonate;Placebo
10 Efficacy of Riluzole in Hereditary Cerebellar Ataxia Completed NCT01104649 Phase 2, Phase 3 riluzole;Placebo comparator
11 STEADFAST Long-Term Safety Extension Completed NCT02797080 Phase 3 interferon γ-1b
12 Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich's Ataxia Study Completed NCT02593773 Phase 3 Interferon γ-1b
13 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Completed NCT02415127 Phase 3 Interferon γ-1b;Placebo
14 Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) Completed NCT01303406 Phase 3 Idebenone;Placebo
15 Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension) Completed NCT00993967 Phase 3 idebenone
16 A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients Completed NCT00905268 Phase 3 idebenone;Placebo
17 Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept Completed NCT00811681 Phase 3 pioglitazone;Placebo
18 Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Completed NCT00697073 Phase 3 Idebenone
19 Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Completed NCT00537680 Phase 3 Idebenone;Idebenone;Placebo
20 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3 Conjugated pneumococcal vaccine (Prevenar)
21 EDS in Ataxia Telangiectasia Patients Recruiting NCT02770807 Phase 3 EDS-EP dose range of ~5-10 mg DSP/infusion;EDS-EP dose range of ~14-22 mg DSP/infusion;Placebo
22 An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Active, not recruiting NCT02889302 Phase 3 KPS-0373;Placebo
23 Trial in Adult Subjects With Spinocerebellar Ataxia Active, not recruiting NCT02960893 Phase 2, Phase 3 BHV-4157;Placebo Comparator
24 An Open Pilot Trial of BHV-4157 Active, not recruiting NCT03408080 Phase 3 BHV-4157
25 Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL) Not yet recruiting NCT03347344 Phase 3 Riluzole;Placebo
26 Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia Terminated NCT00803868 Phase 2, Phase 3 varenicline;placebo
27 A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation Unknown status NCT01489267 Phase 2
28 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia Unknown status NCT01360164 Phase 1, Phase 2
29 A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01004016 Phase 2 KPS-0373;Placebo
30 Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT00863538 Phase 2 KPS-0373
31 Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 Completed NCT00992771 Phase 2 varenicline;placebo
32 Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia Completed NCT01350440 Phase 2
33 Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2) Completed NCT00998634 Phase 2 LITHIUM CARBONATE
34 A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01384435 Phase 2 KPS-0373;KPS-0373;KPS-0373;KPS-0373;Placebo
35 High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration Completed NCT00034242 Phase 2 high-dose intravenous immunoglobulin (IVIG)
36 Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease Completed NCT02147886 Phase 2 Cabaletta for IV infusion once weekly during 24 weeks;Cabaletta for IV infusion once weekly during 24 weeks
37 The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease Completed NCT02039206 Phase 2
38 Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia Completed NCT00202397 Phase 2 Riluzole
39 A First in Human Study of RT001 in Patients With Friedreich's Ataxia Completed NCT02445794 Phase 1, Phase 2 RT001;RT001 comparator
40 A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients Completed NCT02035020 Phase 2 gamma interferon
41 Interferon Gamma-1b in Friedreich Ataxia (FRDA) Completed NCT01965327 Phase 2 Interferon Gamma-1b
42 EPI-743 in Friedreich's Ataxia Point Mutations Completed NCT01962363 Phase 2 EPI-743
43 Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia Completed NCT01728064 Phase 2 Placebo;EPI-743 400 mg;EPI-743 200 mg
44 Efficacy Study of Epoetin Alfa in Friedreich Ataxia Completed NCT01493973 Phase 2 Epoetin alfa;Placebo
45 A Study of Resveratrol as Treatment for Friedreich Ataxia Completed NCT01339884 Phase 1, Phase 2 Resveratrol
46 Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia Completed NCT01035671 Phase 2 alpha-tocopherolquinone (A0001);alpha-tocopherolquinone (A0001);placebo
47 Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia Completed NCT01016366 Phase 2 Lu AA24493;Placebo
48 A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia Completed NCT00897221 Phase 2 Deferiprone oral solution 100mg/mL;Deferiprone oral solution 100 mg/mL
49 Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia Completed NCT00824512 Phase 2 EGb 761 120 mg;Placebo
50 Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia Completed NCT00631202 Phase 2 Epoetin alfa

Search NIH Clinical Center for Spinocerebellar Degeneration

Genetic Tests for Spinocerebellar Degeneration

Genetic tests related to Spinocerebellar Degeneration:

# Genetic test Affiliating Genes
1 Spinocerebellar Tract Degeneration 28

Anatomical Context for Spinocerebellar Degeneration

MalaCards organs/tissues related to Spinocerebellar Degeneration:

38
Brain, Cerebellum, Liver, Eye, Testes, Spinal Cord, Cortex

Publications for Spinocerebellar Degeneration

Articles related to Spinocerebellar Degeneration:

(show top 50) (show all 148)
# Title Authors Year
1
Neuronal vacuolation and spinocerebellar degeneration associated with altered neurotransmission. ( 28677370 )
2017
2
Evaluation of walking smoothness using wearable robotic system curaraAr for spinocerebellar degeneration patients. ( 28814031 )
2017
3
Determination of the time course of caloric nystagmus in patients with spinocerebellar degeneration using caloric step stimulus procedure. ( 28949274 )
2017
4
Intrathecal baclofen pump in spinocerebellar degeneration. ( 27841225 )
2016
5
A Homozygous RAB3GAP1:c.743delC Mutation in Rottweilers with Neuronal Vacuolation and Spinocerebellar Degeneration. ( 26968732 )
2016
6
MRI-based cerebellar volume measurements correlate with the International Cooperative Ataxia Rating Scale score in patients with spinocerebellar degeneration or multiple system atrophy. ( 27536377 )
2016
7
Spinocerebellar degeneration: Discrepancies between clinical and pathological diagnoses. ( 26556659 )
2015
8
"Cerebellar peduncle quarter notes" formed by the superior and middle cerebellar peduncles: comparison with a diffusion tensor study of spinocerebellar degeneration. ( 25749832 )
2015
9
Quantitative analysis of upper-limb ataxia in patients with spinocerebellar degeneration. ( 24781836 )
2014
10
Progressive cerebellar atrophy: hereditary ataxias and disorders with spinocerebellar degeneration. ( 23622410 )
2013
11
Hashimoto's encephalopathy as a treatable adult-onset cerebellar ataxia mimicking spinocerebellar degeneration. ( 23128836 )
2013
12
Acoustic characteristics of ataxic speech in Japanese patients with spinocerebellar degeneration (SCD). ( 22268904 )
2012
13
Anesthetic management of a patient with spinocerebellar degeneration. ( 21772692 )
2011
14
Secondary amenorrhea in a woman with spinocerebellar degeneration treated with thyrotropin-releasing hormone: a case report and in vitro analysis. ( 22152284 )
2011
15
Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study. ( 20809107 )
2010
16
Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT. ( 19286195 )
2009
17
Cognitive impairment in spinocerebellar degeneration. ( 19295212 )
2009
18
Tract-by-tract morphometric and diffusivity analyses in vivo of spinocerebellar degeneration. ( 19021844 )
2009
19
Analysis of subjective evaluations of the functions of tele-coaching intervention in patients with spinocerebellar degeneration. ( 18525137 )
2008
20
Effect of coaching on psychological adjustment in patients with spinocerebellar degeneration: a pilot study. ( 17984151 )
2007
21
Catatonic stupor superimposed on hereditary spinocerebellar degeneration resolved with electroconvulsive therapy. ( 16764981 )
2006
22
Adrenoleukodystrophy manifesting as spinocerebellar degeneration. ( 16804268 )
2006
23
Longitudinal study of bone and calcium metabolism and fracture incidence in spinocerebellar degeneration. ( 17035703 )
2006
24
Thalamic stimulation for disabling tremor in a patient with spinocerebellar degeneration. ( 16155369 )
2005
25
Peripheral nerve pathology in two rottweilers with neuronal vacuolation and spinocerebellar degeneration. ( 16301586 )
2005
26
Influence of repetitive transcranial magnetic stimulation on disease severity and oxidative stress markers in the cerebrospinal fluid of patients with spinocerebellar degeneration. ( 15845214 )
2005
27
[Clinical features and molecular genetics of autosomal recessive spinocerebellar degenerations]. ( 15651291 )
2004
28
Spinocerebellar degeneration with negative electroretinogram: dysfunction of the bipolar cells. ( 15573948 )
2004
29
Spinocerebellar degeneration. ( 14521474 )
2003
30
Mice lacking phosphatidylinositol transfer protein-alpha exhibit spinocerebellar degeneration, intestinal and hepatic steatosis, and hypoglycemia. ( 12788952 )
2003
31
D-cycloserine for the treatment of ataxia in spinocerebellar degeneration. ( 12736088 )
2003
32
Nystagmus-sensation dissociation in spinocerebellar degeneration. ( 14606594 )
2003
33
Transcranial magnetic stimulation alleviates truncal ataxia in spinocerebellar degeneration. ( 11784843 )
2002
34
Ambulatory blood pressure monitoring in patients with spinocerebellar degeneration. ( 12225317 )
2002
35
Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration. ( 11897246 )
2002
36
Reduced pre-movement facilitation of motor evoked potentials in spinocerebellar degeneration. ( 11440743 )
2001
37
Clinical and genetic aspects of spinocerebellar degeneration. ( 10970057 )
2000
38
Vestibular evoked myogenic potentials in patients with spinocerebellar degeneration. ( 11132714 )
2000
39
Diffusion- and T2-weighted MRI of the transverse pontine fibres in spinocerebellar degeneration. ( 11151684 )
2000
40
Chronic vitamin E deficiency causing spinocerebellar degeneration, peripheral neuropathy, and centro-cecal scotomata. ( 10198917 )
1999
41
Therapeutic efficacy of transcranial magnetic stimulation for hereditary spinocerebellar degeneration. ( 10674722 )
1999
42
Parvocellular and magnocellular visual processing in spinocerebellar degeneration and Parkinson's disease: an event-related potential study. ( 10402092 )
1999
43
A novel point mutation in X-linked adrenoleukodystrophy presenting as a spinocerebellar degeneration. ( 10319888 )
1999
44
Branched-chain amino acid therapy for spinocerebellar degeneration: a pilot clinical crossover trial. ( 10397076 )
1999
45
Autosomal dominant spinocerebellar degenerations. Clinical, pathological, and genetic correlations. ( 10367323 )
1999
46
Molecular genetic diagnosis of Friedreich's ataxia in a pedigree with apparent autosomal dominant spinocerebellar degeneration. ( 9886474 )
1999
47
The laryngeal lesion in young dogs with neuronal vacuolation and spinocerebellar degeneration. ( 9684979 )
1998
48
Histopathological and ultrastructural features of feline hereditary cerebellar cortical atrophy: a novel animal model of human spinocerebellar degeneration. ( 9797002 )
1998
49
Late-onset progressive spinocerebellar degeneration in Brittany Spaniel dogs. ( 9678519 )
1998
50
Optic disc edema associated with spinocerebellar degeneration. ( 9672220 )
1998

Variations for Spinocerebellar Degeneration

Expression for Spinocerebellar Degeneration

Search GEO for disease gene expression data for Spinocerebellar Degeneration.

Pathways for Spinocerebellar Degeneration

Pathways related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.41 ATXN1 ATXN2 ATXN3

GO Terms for Spinocerebellar Degeneration

Cellular components related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear matrix GO:0016363 8.96 ATXN1 ATXN3
2 nuclear inclusion body GO:0042405 8.62 ATXN1 ATXN3

Molecular functions related to Spinocerebellar Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.13 ATXN1 ATXN3 GLUD1
2 protein C-terminus binding GO:0008022 8.62 ATXN1 ATXN2

Sources for Spinocerebellar Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....